Understanding how JAG1 affects the immune system in pancreatic cancer
Mechanisms of JAG1-mediated immune suppression in the pancreatic cancer microenvironment
This research explores how a molecule called JAG1 contributes to pancreatic cancer's resistance to immune-boosting treatments, hoping to find new ways to make therapies work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11127786 on NIH RePORTER |
What this research studies
Pancreatic cancer often resists treatments like immunotherapy because of a protective environment around the tumor. This project aims to understand how a specific molecule, JAG1, helps create this protective environment by affecting certain immune cells called dendritic cells. These dendritic cells are crucial for helping the body's T cells fight cancer, but they are often suppressed in pancreatic cancer. By learning how JAG1 interferes with these immune cells, we hope to find new strategies to overcome treatment resistance.
Who could benefit from this research
Good fit: This foundational research is for patients with pancreatic cancer who are interested in understanding the biological reasons behind treatment resistance and potential future therapies.
Not a fit: Patients seeking immediate new treatments or direct clinical trial participation would not directly benefit from this early-stage laboratory research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that make immunotherapies more effective for people with pancreatic cancer.
How similar studies have performed: Other studies have shown that similar signaling pathways play a role in immune suppression in other cancers, suggesting this approach has a basis in existing knowledge.
Where this research is happening
Houston, United States
- Methodist Hospital Research Institute — Houston, United States (Active)
Researchers
- Principal investigator: Zhou, Lan — Methodist Hospital Research Institute
- Study coordinator: Zhou, Lan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.